Loading clinical trials...
Loading clinical trials...
A Randomized, Phase 2, Study to Assess the Safety and Activity of CRLX101, a Nanoparticle Formulation of Camptothecin, in Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed One or Two Previous Regimens of Chemotherapy
Conditions
Interventions
CRLX101
Best Supportive Care
Locations
25
Russia
State Medical Institution Republican Oncology Center
Saransk, Respublika Mordoviya, Russia
State Medical Institution Republic Clinical Oncological Center under the Healthcare Ministry of Tatarstan Republic
Kazan', Tatarstan Republic, Russia
Arkhangelsk Regional Clinical Oncology Center
Arkhangelsk, Russia
State Healthcare Institution: Bryansk Regional Oncology Center
Bryansk, Russia
Chelyabinsk Regional Clinical Oncology Center
Chelyabinsk, Russia
Kursk Regional Oncology Center
Kursk, Russia
Start Date
June 1, 2011
Primary Completion Date
February 1, 2013
Completion Date
October 1, 2014
Last Updated
May 28, 2020
NCT06305754
NCT07190248
NCT07100080
NCT07195695
NCT06357533
NCT06731413
Lead Sponsor
NewLink Genetics Corporation
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions